ContextWarfarin has been shown to be highly efficacious for preventing thromboembolism in
atrial fibrillation in randomized trials, but its effectiveness and safety in clinical practice is …

Purpose: To characterize the efficacy and safety of anticoagulants and antiplatelet agents for
prevention of stroke in patients with atrial fibrillation. Data Sources: Randomized trials …

Atrial fibrillation (AF) is an important risk factor for stroke. According to a pooled analysis of
controlled clinical trials with warfarin, anticoagulation therapy reduces stroke risk by 62 …

Background Although several new antithrombotic agents have been developed for stroke
prevention in patients with nonvalvular atrial fibrillation (AF), many patients will continue to …

Background Randomized trials demonstrate a clear benefit of anticoagulation in patients
with atrial fibrillation at risk of stroke, but the proportion of eligible patients who are treated …

Background: Atrial fibrillation is a strong independent risk factor for stroke. Purpose: To
characterize the efficacy and safety of antithrombotic agents for stroke prevention in patients …

Background and Purpose—Warfarin is the most effective stroke prevention medication for
high-risk individuals with atrial fibrillation, yet it is often underused. This study examined the …

Background: Several recent randomized clinical trials of anticoagulation in atrial fibrillation
have demonstrated significant reduction in stroke rates with a small incidence of bleeding …

OBJECTIVE: Appropriate use of drugs to prevent thromboembolism in patients with atrial
fibrillation (AF) involves comparing the patient's risk of stroke and risk of hemorrhage. This …

BACKGROUND: Atrial fibrillation is associated with substantial mortality and morbidity from
stroke and thromboembolism. Despite an efficacious oral anticoagulation therapy (warfarin) …